Indomethacin for prevention of heterotopic ossification. A randomized controlled study in 41 hip arthroplasties

Acta Orthop Scand. 1993 Dec;64(6):639-42. doi: 10.3109/17453679308994587.

Abstract

The effect of indomethacin 25 mg 3 times daily during the first 2 postoperative weeks in preventing heterotopic bone formation after cemented total hip arthroplasty was investigated in a randomized, double-blind and placebo-controlled clinical trial on 57 patients. 16 patients were secondarily excluded, leaving 19 patients in the indomethacin group and 22 patients in the placebo group. Evaluated from the 3-month radiographs, 18/19 indomethacin patients developed either no or only the milder Grade 1 ossification. In contrast, 11/22 placebo patients developed Grade 2 or 3 ossifications. Our observations favor indomethacin prophylaxis for 2 weeks in cemented arthroplasty of the hip.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Double-Blind Method
  • Female
  • Hip Prosthesis*
  • Humans
  • Indomethacin / therapeutic use*
  • Male
  • Middle Aged
  • Ossification, Heterotopic / prevention & control*
  • Postoperative Complications / prevention & control

Substances

  • Indomethacin